NCT06335173Phase 2Active not recruiting

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

Study sponsor: Acumen Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-10-29Actual
Enrollment · participants542Actual
Source updated2026-11-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Oct 2026. After: 29 Oct 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview